Association of Immune Checkpoint Inhibitors With Otologic Symptoms: A Propensity Score-Matched Study.
Cancer immunotherapy may increase hearing and balance problems, helping doctors better prepare and monitor patients.
Thompson ZE et al. conducted a propensity score-matched analysis to assess the association between immune checkpoint inhibitor therapy and otologic adverse events. The study provides evidence that ICI therapy may be associated with increased risk of hearing and vestibular symptoms, with implications for patient counseling and monitoring protocols.
What the study was
- Study design
- Propensity score-matched comparative study (retrospective)
- Population
- Cancer patients receiving immune checkpoint inhibitors vs. propensity-matched controls
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- The Laryngoscope
Why it surfaced
ICI-related otologic adverse events are a clinically actionable safety signal; propensity-matched design provides reasonable evidence quality; finding has immediate monitoring implications for oncology practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.